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Abstract: DmmA is a haloalkane dehalogenase (HLD) identified and characterized from the
metagenomic DNA of a marine microbial consortium. Dehalogenase activity was detected with
1,3-dibromopropane as substrate, with steady-state kinetic parameters typical of HLDs (Km 5 0.24
6 0.05 mM, kcat 5 2.4 6 0.1 s
21). The 2.2-A˚ crystal structure of DmmA revealed a fold and active
site similar to other HLDs, but with a substantially larger active site binding pocket, suggestive of
an ability to act on bulky substrates. This enhanced cavity was shown to accept a range of linear
and cyclic substrates, suggesting that DmmA will contribute to the expanding industrial
applications of HLDs.
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Introduction
Haloalkane dehalogenases (HLDs) remove halogens
from alkanes by hydrolysis, producing an alcohol, a
halide ion, and a proton. These dehalogenating
enzymes are of long-standing interest for industrial
applications such as degradation of environmental
pollutants1,2 and biocatalysis.3 Newer applications
include remediation of chemical weapons,4 biosens-
ing,5,6 and cellular imaging.7 The applications for
HLDs are growing with knowledge of their func-
tional and structural properties.
Each HLD has a unique substrate selectivity,
which can include chlorinated, brominated, and io-
dinated alkanes of varying length. Some HLDs also
act on ring-containing substrates, or those with alco-
hol, ether, nitrile, or alkene functional groups.8 Sub-
strate selectivity is not easily predicted by sequence
analysis. For HLDs of known structure, the size and
shape of the active-site cavity are better predictors
of substrate preference than is phylogenetic analy-
sis.8 The natural substrates are, in general,
unknown.
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HLDs are members of the a/b hydrolase super-
family, with the active site located between a con-
served core subdomain and a more variable lid
structure. The HLD active site departs from the typ-
ical a/b hydrolase catalytic triad by the replacement
of the common Ser nucleophile with an Asp and the
addition of two halide-stabilizing residues (Trp and
Trp/Asn) to form a ‘‘catalytic pentad.’’9 The side
chains of the catalytic pentad are identically posi-
tioned in the active site cleft of all HLDs of known
structure, although some pentad residues vary in
their locations in the primary sequence. This
sequence-location difference of the catalytic pentad
residues defines three evolutionary subfamilies of
HLDs.10 Two structures are known from evolution-
ary subfamily I (DhlA11–13 and DppA14), and four
from subfamily II (DhaA,15,16 LinB,17–20 DbjA,21 and
Rv257822). Several structures include bound sub-
strates, products, or covalent intermediates, which
together with many kinetic studies, led to a detailed
reaction mechanism for this enzyme class.9
DmmA is a putative HLD of subfamily II.10 This
protein was originally annotated as CurN, and pre-
sumed to be the final gene product of the curacin A
biosynthetic gene cluster23 from the marine cyano-
bacterium Lyngbya majuscula (now designated
Moorea producta24). However, resequencing revealed
the authentic 30 end of the gene cluster, which lacks
curN,25 suggesting that dmmA was cloned as part of
a chimeric cosmid from the original metagenomic
DNA library.23 Herein, we present the crystal struc-
ture and HLD activity of DmmA.
Results
Biological source of DmmA (formerly CurN)
In the original curacin pathway sequencing,23 DNA
encoding 64 amino acids at the CurN N-terminus
overlapped with DNA encoding the CurM C-termi-
nus in a different reading frame. This unusually
long overlap and peculiarities of the CurM protein
sequence led us to isolate a new cosmid, and to rese-
quence the curM-curN region of the gene cluster,
resulting in a corrected 30 terminus that lacked
curN.25 In addition, no CurN coding sequence was
identified by amplification from M. producta (for-
merly L. majuscula) genomic DNA, nor was CurN
located in the recently sequenced M. producta 3L ge-
nome.26 Furthermore, the G þ C content of curN
(61%) contrasts with the rest of the curacin biosyn-
thetic gene cluster (45.5%). The scaffolds used to
assemble the M. producta genome ranged from 37 to
66% G þ C content, with the great majority falling
between 40 and 45%.26 In addition, CurN (now
referred to as DmmA (dehalogenase A from a marine
microbe) in accord with other dehalogenases of
unknown biological function8) has high similarity
(50%) to HLDs from other marine bacteria,
although none are from the cyanobacterial phyla. From
these data, we conclude that curN (dmmA) is most
likely a product of one of the organisms that grew in
close association with the M. producta field isolate
whose metagenomic DNA cosmid library was used to
sequence the cur gene cluster. It is evident that the 30
end of the curacin gene cluster concatenated with curN
(dmmA) genetic material from one of the heterotroph
bacteria that was growing on the M. producta filament
at the time of cosmid preparation.
Because the biological source and the natural
termini of DmmA are uncertain, we turned to
sequence analysis to design dmmA constructs for
protein expression. HLD homologs have C-termini of
very similar length and sequence to the DmmA C-
terminus, but the N-termini are poorly conserved
and of variable length.10 In addition, DmmA amino
acids 1-40 are predicted to be unstructured. Strong
sequence conservation among subfamily-II HLDs
begins at DmmA residue 48. This evidence could
suggest that the N-terminus of DmmA is not in the
original gene, however several considerations led us
to consider the full open reading frame as the natu-
ral length of DmmA. First, the DNA sequence
upstream of the putative translation start site con-
tains sequence motifs and spacers similar to pro-
karyotic r70 promoter regions and ribosome binding
sequences (Supporting Information Fig. 1). In addi-
tion, several other annotated HLDs have N-termini
of similar length to DmmA.10 Thus, we conclude
that the natural protein likely includes all the resi-
dues encoded in the curN (dmmA) open reading
frame. Two dmmA constructs were made, one encod-
ing the full-length protein (DmmAlong, residues
1-341) and one with a 43-residue N-terminal trunca-
tion (DmmAshort, residues 44-341) to produce a
potentially more structured N-terminus (Supporting
Information Fig. 2). Both DmmAshort and DmmAlong
were produced in high yield, as stable and soluble
proteins in an E. coli expression system.
HLD activity
As for many other HLDs, the natural substrate for
DmmA is unknown. Small di-halogenated alkanes
are typical substrates to assess the activity of HLDs.
We chose 1,3-dibromopropane, a standard substrate,
Table I. DmmA Activity Toward Halogenated
Substrates
Construct Substrate % Activitya
DmmAshort 1,3-dibromopropane 100
DmmAshort 1,6-dibromohexane 3.5 6 0.7
DmmAshort bromocyclohexane 14.8 6 0.6
DmmAshort 1,6-dichlorohexane 3.7 6 1.4
DmmAshort 1,6-diiodohexane 3.2 6 0.7
DmmAlong 1,3-dibromopropane 10 6 2
a Normalized to activity of DmmAshort with 1 mM 1,3-
dibromopropane.
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for DmmA assays. HLD activity was tested in a
colorimetric assay to detect the production of pro-
tons.27,28 Both DmmAshort and DmmAlong were active
in this assay, however DmmAshort exhibited tenfold
higher activity than the longer form of the protein
(Table I), suggesting that the N-terminus may inter-
fere with catalysis. Steady-state kinetic constants
were determined for DmmAshort (Table II), which
revealed that these parameters are comparable to
other HLDs.15,27,29 DhlA has threefold greater cata-
lytic efficiency than DmmA for 1,3-dibromopropane
(fourfold lower kcat, 12-fold lower Km),
27 whereas
DhaA has a nearly equal kcat and a 50-fold lower Km
for 1,3-dibromopropane resulting in a 50-fold greater
catalytic efficiency.29
Structure of DmmA
We solved crystal structures for both DmmAshort and
DmmAlong (Table III). The first structure was deter-
mined from selenomethionyl DmmAshort (2.2 A˚).
DmmAlong (2.9 A˚) was solved from the DmmAshort
structure. The short and long variants crystallized
under different conditions in different crystal forms,
each with two polypeptides per asymmetric unit.
The two structures thus provide four independent
views of the DmmA dehalogenase.
Due to the higher-resolution of DmmAshort, our
efforts focused on analysis of that form of the protein.
DmmA adopts the a/b hydrolase fold as expected
[Fig. 1(A)], consisting of core and lid sub-domains
with the active site at the top of the core, which is
covered by the lid [Fig. 1(A,B)]. DmmAshort and
DmmAlong are identical within experimental error
(root-mean-square deviation (RMSD) ¼ 0.32 A˚ for
298 Ca atoms). The DmmAshort structure is complete
with no disordered residues. In DmmAlong, six addi-
tional N-terminal residues are visible compared with
DmmAshort, but 37 residues at the N-terminus are
disordered [Fig. 1(C)].
DmmA oligomeric state
A common protein-protein contact exists in the unre-
lated crystal forms of DmmAlong and DmmAshort. The
contact has twofold (non-crystallographic) symmetry,
Table II. Steady State Kinetic Parameters of
DmmAshort
kcat (s
1) Km (mM) kcat/Km (M
1s1)
2.4 6 0.1 0.24 6 0.05 1.0 6 0.3  104
Table III. Crystallographic Summary
DmmAshort (SeMet)
DmmAshort (SeMet)
1,5-dibromopentane soaked DmmAlong
Diffraction Data
Space group P62 P62 P3121
X-ray source APS 23-ID-D APS 23-ID-D APS 23-ID-D
a, b, c (A˚) 99.8, 99.8, 122.0 100.3, 100.3, 121.4 144.7, 144.7, 105.0
a, b, c () 90, 90, 120 90, 90, 120 90, 90, 120
Wavelength (A˚) 0.97939 0.92003 0.97939
dmin (A˚) 2.20 (2.28–2.2)
a 2.10 (2.18–2.10) 2.50 (2.50–2.64)
Avg I/rI 13.2 (2.9) 16.7 (2.1) 10.4 (3.5)
Rsymm
b 0.122 (0.549) 0.118 (0.75) 0.171 (0.607)
Completeness 100.0 (99.9) 99.7 (97.6) 100 (100)
Avg. redundancy 5.8 (5.2) 10.5 (7.6) 9.6 (8.6)
Unique reflections 35,082 40,262 44,165
Refinement
Data range (A˚) 86.39–2.20
No. reflections 34,919
Rwork/Rfree
c 0.139/0.177
RMS deviations
Bonds (A˚) 0.009
Angles () 1.195
Avg B-factors (A˚2)
Protein 23.4
Ligand/Ion 53.3
Water 35.0
Ramachandran
Allowed 99.66%
Outliers 0.34%
Number of Atoms
Protein 4649
Ligand/Ion 18
Water 497
a Outermost shell in parentheses.
b Including anomalous differences.
c The Rfree data set included a random 5% of reflections.
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suggesting that the protein may be dimeric [Fig.
1(D)]. The primary interaction occurs within the HLD
core between a10 and b8, and is comprised of both
hydrophobic and hydrophilic contacts and buries only
four water molecules. The additional six ordered resi-
dues in DmmAlong
(residues 38–43) associate with the
partner subunit at this interface, resulting in a larger
buried surface area in DmmAlong compared to DmmA-
short (980 A˚
2 vs. 610 A˚2) [Fig. 1(D)]. The small size of
the interface led us to question whether it exists in
solution. Other HLDs have been characterized as
monomers, dimers, or dimers only under low-salt con-
ditions. Among HLDs of known structure, only DbjA
is dimeric in solution.36 The helix a10 is central to the
subunit contacts in both DmmA and DbjA, but the
interfaces otherwise differ (Supporting Information
Fig. 3).
The quaternary structure in solution was probed
by analytical gel filtration chromatography. Both
DmmAshort and DmmAlong eluted with apparent
Figure 1. Structure of DmmA. A: DmmA polypeptide. The stereo ribbon diagram is colored as a rainbow from blue at the N-
terminus to red at the C-terminus with catalytic pentad residues in stick form with magenta C. B: Topology diagram. The a/b
hydrolase core is conserved among all a/b hydrolases and the lid is conserved among haloalkane dehalogenases. Residues
of the catalytic pentad are labeled. C: Superposition of DmmAlong (gray) and DmmAshort (rainbow main-chain, magenta active
site). Six additional residues on the N-terminus of DmmAlong are visible. D: Protein-protein contact in the crystal structures.
Only the left molecules of DmmAshort (rainbow main-chain, magenta active site) and DmmAlong (gray, purple N-terminal
extension) are superimposed. The near superposition of the right molecules highlights the similar interfaces. Contacts of a10,
b8, and N-terminal extension are labeled.
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molecular weights intermediate between calculated
values for the monomer and the dimer (48 kDa
observed vs. 34.6 kDa for a DmmAshort monomer,
and 59 kDa vs. 38.8 kDa for DmmAlong) (Supporting
Information Fig. 4). This result implies a dynamic
equilibrium between monomeric and dimeric forms,
however the retention volume did not change over a
20-fold concentration range of either DmmAshort or
DmmAlong. In addition, the larger buried surface in
the putative DmmAlong dimer compared to DmmA-
short does not result in a more dimeric retention vol-
ume. Thus, we conclude that the interface observed
in the crystal structures does not represent an inter-
face in solution and that DmmA is monomeric. The
Figure 2. DmmA active site. A: DmmA active site showing catalytic pentad (sticks), Cl and malonate. B: Schematic of the
DmmA active site showing the acyl-enzyme intermediate. The halide-stabilizing residues (Asn78 and Trp 145) bind the halide
released when generating the acyl enzyme intermediate. The acyl enzyme on Asp144 will subsequently be hydrolyzed by a
water activated by His315 C. Active site of subfamily II haloalkane dehalogenases, based on superposition of core Ca atoms.
The catalytic pentad is shown in sticks and bound halide ion as a sphere for DmmA (green C), LinB 1IZ819 (orange C),
Rv2578 2O2I22 (yellow C), DbjA 3A2M21 (purple C), and DhaA 1CQW15 (mauve C). Bound malonate is shown for DmmA and
bound product, 1,3-propandiol, for Rv2578 (yellow C) and LinB (orange C).
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aberrant elution volumes may result from the
dynamic behavior of a monomeric DmmA.
DmmA active site
The active site has an intact and well ordered cata-
lytic pentad, consisting of the nucleophile (Asp144),
base (His315), acid (Glu168), and two halide-stabiliz-
ing residues (Trp145 and Asn78) [Fig. 2(A,B)]. The
nucleophile (Asp144), base (His315), and Trp145 are
conserved in all HLDs. Asn78 is conserved in subfami-
lies II and III, and Glu168 is present only in subfamily
II. The catalytic pentad resides are in an otherwise
hydrophobic chamber that is accessed through an en-
trance tunnel. This feature and the location of the
pentad are well conserved in structures of all subfam-
ily II HLDs [Fig. 2(C)]. Density resembling malonate,
a component of the crystallization solution, was found
in the active site cleft [Fig. 2(A), Supporting Informa-
tion Fig. 5]. A product alcohol is bound at this position
in structures of several other HLDs [Fig. 2(C)]. Differ-
ence density for a stronger scatterer than water (peak
height 7.7 r) appeared in the putative halide-binding
site within hydrogen bonding distance of Trp145 and
Asn78, the halide-stabilizing residues [Fig. 2(A), Sup-
porting Information Fig. 5). A halide occupies this
position in the structures of several other HLDs [Fig.
2(C)]. The halide-binding site was confirmed by Br
anomalous scattering from a crystal of DmmAshort
soaked in 1,5-dibromopentane prior to data collection
at the energy of the bromine K absorption edge. Br
Figure 3. DmmA and other HLDs. A: Superposition of DmmA (rainbow main-chain, magenta active site) and the HLD DhaA
(1BN715). Differences in the lid-to-core linker and a4 are labeled. B: Active site cavity of DmmA and other type II haloalkane
dehalogenases: DmmA (green), LinB 1IZ819 (orange), Rv2578 2O2I22 (yellow), DbjA 3A2M21 (purple), and DhaA 1CQW15
(mauve). The gray surface represents the internal volume of the cavity. Residues that form the forward surface are omitted.
Active site residues are shown in sticks (cyan C, blue N, red O).
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binding resulted in an anomalous difference peak of
height 9 r; no density was observed for the hydroxyl
product (Supporting Information Fig. 6).
Comparison to other HLDs
The DmmA structure is similar to structures of
other subfamily II HLDs (0.5–0.7 A˚ RMSD for 219–
226 Ca atoms of proteins that are 38–48% identical
overall to DmmA). The largest difference between
the most similar structure, DhaA, and DmmA is in
lid helix a4 and the core-to-lid linker from b6 to a4
[Fig. 3(A)]. As expected, DmmA is less similar to the
subfamily I HLDs, DhlA (1.4 A˚ RMSD for 203 Ca)
and DppA (1.9 A˚ for 209 Ca), which have lower over-
all sequence identity to DmmA.
Structure-function studies of other HLDs have
demonstrated that the size of the active site cavity
and entry tunnel play a role in substrate specificity8
and chiral selectivity.21 DmmA has a larger entry
tunnel and wider substrate cleft than other HLDs
[Fig. 3(B)]. This difference is due primarily to the
position of lid helix a4 and the preceding loop, and
to a lesser extent to amino acid substitutions within
the cavity. The loop and helix a4 are the parts of the
DmmA structure that differ most from other HLDs.
Other HLDs with large active sites17,21 have very
broad substrate specificity and react well with larger
substrates.8 DmmA, with an even larger active site,
should accommodate substrates of greater size and
shape diversity. To test this, we assayed DmmA for
dehalogenase activity with several halogenated mol-
ecules larger than the 1,3-dibromopropane standard
substrate (1,6-dibromohexane, 1,6-dichlorohexane,
1,6-diiodohexane, and bromocyclohexane) (Table I).
In contrast to those tested previously,8 DmmA has
greater activity for the bromocyclohexane compared
to the larger straight-chain substrates. This observa-
tion is consistent with the wide cavity of DmmA and
suggests that it has robust activity toward other
bulky substrates.
Discussion
This work establishes that DmmA is a HLD. The ki-
netic properties of DmmA with a standard substrate,
1,3-dibromopropane, are within the range reported
for other HLDs. However, as for most HLDs, the
natural substrates are unknown. Of the two protein
variants studied, DmmAshort was significantly faster
than DmmAlong, exhibiting tenfold greater activity.
Although most of the additional 43 residues on the
N-terminus of DmmAlong are disordered, they may
interfere with substrate access to the active site,
resulting in the reduced activity observed for the
longer form of the protein.
The DmmA structure has the same fold and
active site position as other HLDs, as expected.
Nevertheless, DmmA has unique structural features
that set it apart from other enzymes within this
class. The active site cavity of DmmA is significantly
larger than the cavity of other homologs, which was
not predictable from straightforward sequence com-
parisons to other HLDs of known structure. Instead,
sequence differences led to subtle structural varia-
tion in the position of helix a4 and the core-to-lid
linker, which resulted in a large cavity volume. The
size of amino acid side chains lining the active site
pocket makes a secondary contribution to the cavity
size. The larger cavity volume may confer an ability
to accept a wide range of large, bulky substrates
compared to other HLDs. Among the larger sub-
strates tested, DmmA had a preference for the bulky
bromocyclohexane over corresponding linear mole-
cules. This suggests that the natural DmmA sub-
strate may bear a halogenated ring system. The
large active site also suggests the value of DmmA as
a potential chemoenzymatic tool for large substrates.
The ultimate biological source of DmmA is
unknown, as attempts to amplify dmmA from M. pro-
ducta (formerly L. majuscula) DNA or to find dmmA
in the genome sequence have been unsuccessful.
dmmA (originally annotated as curN23) was originally
found in the cosmid library developed from anM. pro-
ducta field isolate, which also contained bacterial
symbionts or associants as a microbial consortium. To
our knowledge, no other HLD has been found in a cya-
nobacterium, which also suggests an origin outside
M. producta, in a symbiont or associated bacterium.
Presumably, the natural function of DmmA is to deha-
logenate molecules present in the native marine envi-
ronment of M. producta. In this respect, M. producta
has been a rich source of halogenated metabolites,
including in this strain, barbamide, which possesses a
trichloromethyl group,37 and in another strain, jamai-
camide, which possesses vinyl chloride and alkynyl
bromide groups.38 Despite its orphan status, the large
active-site cavity poises DmmA for development as a
new biotechnology tool.
Materials and Methods
Cloning, protein expression, and purification
Gene fragments encoding DmmA were generated
from cosmid pLM17,23 inserted into the pET-24b vec-
tor, and verified by sequencing to form pDmmAlong
(encoding residues 1-341) and pDmmAshort (encoding
residues 44-341). E. coli strain BL21(DE3) was
transformed with the expression plasmid, grown at
37C in 1 L 2xYT to an OD600 of 0.5, cooled to 18C,
induced with IPTG (final concentration 0.4 mM) and
grown for an additional 18 h. Selenomethionyl
(SeMet) DmmAshort was produced in the same strain
in SeMet minimal media.39
All purification steps were performed at 4C.
The cell pellet from 1 L of cell culture was resus-
pended in 40-mL Buffer A (20 mM Tris pH 7.9, 500
mM NaCl, 10% glycerol) plus 20-mM imidazole,
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lysed by sonication, and the soluble fraction loaded
onto a 5-mL HisTrap Ni NTA column (GE Health-
care). DmmA was eluted with Buffer A with a linear
gradient of 20–650 mM imidazole. DmmA was fur-
ther purified by size exclusion chromatography with
a HiPrep 16/60 Sephacryl S100 HR column (GE
Healthcare) prequilibrated with Buffer A. DmmA
was concentrated to 14 mg/mL, flash frozen in liquid
N2, and stored at 80C. SeMet DmmAshort was
purified as the wild type with addition of 2 mM
DDT to Buffer A during the size exclusion step.
Yields per 1 L culture were 150 mg for DmmAshort,
80 mg for DmmAlong, and 15 mg for SeMet
DmmAshort.
Crystallization
Crystals of DmmAshort (native and SeMet) grew by
vapor diffusion at 20C within 24 h from a 1:1 mix
of protein stock (6 mg/mL DmmAshort in Buffer A)
and well solution (2.2 M sodium malonate pH 7.0,
5% glycerol). Crystals of DmmAlong formed at 20
C
within 24–48 h from a 1:1 mix of protein stock (14
mg/mL DmmAlong in Buffer A) and well solution (0.6
M lithium sulfate, 27.5% PEG3350, and 0.1 M BisT-
ris pH 5.5). Crystals of DmmAlong were cyropro-
tected by a 5–10 s transfer to a mixture of well solu-
tion also containing 25% PEG400.
Data collection and structure determination
Data were collected at the GM/CA-CAT beamline
23ID-D at the advanced photon source (APS) at
Argonne National Lab (Argonne, IL). A 2.2 A˚ single-
wavelength anomalous diffraction dataset was col-
lected at the wavelength of peak absorption at the
selenium edge from a DmmAshort SeMet crystal. A
2.9 A˚ dataset was collected from a DmmAlong crystal.
All data were processed using the HKL2000 suite.40
Determination of selenium atomic positions, experi-
mental phasing, density modification phase refine-
ment, and initial model building were performed
using the programs SOLVE and RESOLVE.41,42 And
22 of the 24 expected selenium positions were identi-
fied. The model was finished manually in COOT.43
REFMAC530 from the CCP4 suite31 was used for
refinement. The DmmAlong structure was solved by
molecular replacement in Phaser32 using DmmAshort
as a search model. Model quality was evaluated with
MolProbity.33 Figures were made using PyMOL34
and hollow.35 Electron density was complete
throughout the polypeptide chain for both polypep-
tides for DmmAshort (residues 44-341) and DmmAlong
(residues 38–341). No density was observed for the
C-terminal His tag of either DmmA variant or for
the first 37 residues of DmmAlong.
Enzyme assay
Activity was measured using a pH indicator dye-
based colorimetric method.27,28 Substrate [0.1–6.0
mM 1,3-dibromopropane (Aldrich)] was prepared in
an indicator solution (20 lg/mL phenol red, 20 mM
Na2SO4, 1 mM EDTA, 1 mM Hepes pH 8.2). Reac-
tions were initiated by addition of DmmAshort (1 lM
final concentration, 100-lL final volume). Absorb-
ance at 550 nm was monitored at 5-second intervals
during the reaction to detect the decrease in pH gen-
erated by the release of Hþ. Parallel negative con-
trols lacking the enzyme or substrate were used to
correct for nonenzymatic dehalogenation or pH
change. A standard curve relating absorbance at 550
nm to [Hþ] was used to convert absorbance to [Hþ].
The initial rates were fit using KaleidaGraph to the
Michaelis-Menten equation (vinitial ¼ ([enzyme]*[sub-
strate]*kcat)/(Kmþ[substrate]) to obtain steady state
kinetic constants. Comparison with other substrates
(1,6-dibromohexane (Acros), 1,6-dichlorohexane
(Aldrich), 1,6-diiodohexane (Aldrich), bromocyclohex-
ane (Aldrich)) were performed at 1 mM substrate
concentration in duplicate and normalized to the
percent of 1,3-dibromopropane activity.
PDB Coordinates
Coordinate and structure factors for DmmAshort
have been deposited in the Protein Data Bank with
accession number 3U1T.
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